Logo Image
News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Event Calendar

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Event Calendar
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement

Dr. Ryan Taft

Advertisement

Dr. Ryan Taft is chief scientific officer at iHope/Genetic Alliance.

Articles by Dr. Ryan Taft

Ryan Taft and Stacy Musone

Expanding Access to Whole-Genome Testing for Children: Q&A with Drs. Ryan Taft and Stacy Musone

ByMike Hollan,Dr. Ryan Taft,Stacy Musone
April 3rd 2026

Members of PacBio and iHope discuss collaboration and the global state of genomic testing.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on PharmExec

    1

    FDA Approves Lipfendra to reduce LDL-C in Adults with Hypercholesterolemia

    2

    FDA Approves Revtorpyk for Treatment of Advanced HR-Positive, HER2-Negative Breast Cancer

    3

    Insilico Medicine Enters $2.5 Billion Alliance with Bora Pharmaceuticals

    4

    Eli Lilly to Acquire AtaiBeckley for $2.8 Billion

    5

    Nuvation Bio’s Approach to Building a Compelling Narrative

    • About
    • Advertise
    • Contact Us
    • Editorial Board
    • Editorial Submission Guidelines
    • Do Not Sell My Personal Information
    • Privacy Policy
    • Terms and Conditions
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us